Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

126
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
126
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

108
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
108
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.2K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Automated Parallel Synthesis Accelerates Virtual Screening Hit Discovery.

Journal of the American Chemical Society·2026
Same author

Development of Indole-3-yl-methylene-thiobarbital Derivatives as Inhibitors of HDAC8 Enzyme Activity.

Journal of medicinal chemistry·2026
Same author

Impact of Achilles tendon rupture on performance and career outcomes in NFL players: a matched cohort study.

The Physician and sportsmedicine·2026
Same author

Scaffold-based evaluation metrics for fair comparison of molecular generators.

Journal of cheminformatics·2026
Same author

Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public Reports.

Clinical pharmacology and therapeutics·2026
Same author

CLO26-130: Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Pancreatic Ductal Adenocarcinoma With Isolated Peritoneal Metastases: A Meta Analysis and Systematic Review.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

相关实验视频

Updated: Sep 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

在寻找美丽的分子:药物设计的生成模型的视角

Remco L van den Broek1, Shivam Patel2, Gerard J P van Westen1

  • 1Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, Leiden 2333CC, the Netherlands.

Journal of chemical information and modeling
|September 2, 2025
PubMed
概括

生成型人工智能可以通过设计"美丽"的分子来加速药物发现,优先考虑合成性,安全性和有效性. 整合人类专业知识,特别是通过强化学习与人类反,对于引导人工智能开发具有治疗价值的候选药物至关重要.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.0K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.7K

相关实验视频

Last Updated: Sep 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.0K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.7K

科学领域:

  • 药物发现中的人工智能
  • 计算化学
  • 医学化学

背景情况:

  • 生成型人工智能 (GenAI) 通过探索化学空间和设计具有理想性质的分子来发现新药.
  • 尽管取得了进展,但GenAI在潜在药物发现中的价值仍然未被证明,这凸显了潜力和应用之间的差距.

研究的目的:

  • 定义成功的药物发现生成人工智能 (GADD) 的标准,重点是生成与治疗目标一致的"美丽"分子.
  • 强调人类专业知识和反在引导人工智能模型向临床相关药物候选者的关键作用.

主要方法:

  • 专注于GADD的五个关键考虑因素:化学合成性,ADMET特性,特定目标结合,多参数优化 (MPO) 功能和人类反.
  • 提出强化学习与人类反 (RLHF) 作为一种将GenAI输出与专家判断对齐的方法,类似于在大型语言模型中的使用.

主要成果:

  • 一个分子的"美丽"取决于环境,
  • 虽然MPO框架有助于优化,但它们不能完全取代毒品猎人的经验.
  • RLHF对于塑造基因AI对治疗性调整分子的行为至关重要.

结论:

  • 为了获得成功的GADD, 不仅要产生新型分子,还要创造出超越传统方法的"美丽"分子.
  • 未来的GADD进展取决于改进的物业预测,可解释的AI系统和人类反循环的整合.
  • 最终,人工智能产生的候选药物的成功由经验丰富的药物猎人和临床结果来判断.